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Influence of Nodal signalling on
pluripotency factor expression, tumour cell
proliferation and cisplatin-sensitivity in
testicular germ cell tumours
K. Harpelunde Poulsen1,2, J. E. Nielsen1,2, B. Grønkær Toft3, U. N. Joensen4, L. J. Rasmussen5, M. Blomberg Jensen1,
R. T. Mitchell6, A. Juul1,2, E. Rajpert-De Meyts1,2 and A. Jørgensen1,2*
Abstract
Background: Testicular germ cell tumours (TGCTs) are characterised by an overall high cisplatin-sensitivity which
has been linked to their continued expression of pluripotency factors. Recently, the Nodal signalling pathway has
been implicated in the regulation of pluripotency factor expression in fetal germ cells, and the pathway could
therefore also be involved in regulating expression of pluripotency factors in malignant germ cells, and hence
cisplatin-sensitivity in TGCTs.
Methods: We used in vitro culture of the TGCT-derived cell line NTera2, ex vivo tissue culture of primary TGCT
specimens and xenografting of NTera2 cells into nude mice in order to investigate the consequences of
manipulating Nodal and Activin signalling on pluripotency factor expression, apoptosis, proliferation and cisplatin-
sensitivity.
Results: The Nodal signalling factors were markedly expressed concomitantly with the pluripotency factor OCT4 in
GCNIS cells, seminomas and embryonal carcinomas. Despite this, inhibition of Nodal and Activin signalling either
alone or simultaneously did not affect proliferation or apoptosis in malignant germ cells in vitro or ex vivo.
Interestingly, inhibition of Nodal signalling in vitro reduced the expression of pluripotency factors and Nodal
pathway genes, while stimulation of the pathway increased their expression. However, cisplatin-sensitivity was not
affected following pharmacological inhibition of Nodal/Activin signalling or siRNA-mediated knockdown of the
obligate co-receptor CRIPTO in NTera2 cells in vitro or in a xenograft model.
Conclusion: Our findings suggest that the Nodal signalling pathway may be involved in regulating pluripotency
factor expression in malignant germ cells, but manipulation of the pathway does not appear to affect cisplatin-
sensitivity or tumour cell proliferation.
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Background
Testicular germ cell tumours (TGCTs) in young adults ori-
ginate from a common precursor, germ cell neoplasia in
situ (GCNIS, previously known as carcinoma in situ) [1–3].
GCNIS cells are considered to be transformed gonocytes
that have failed to differentiate to pre-spermatogonia during
fetal testis development, most likely as a consequence of al-
tered signalling from the somatic niche [3]. The arrest of
gonocyte maturation is regarded as the initial step in the
testicular cancer pathogenesis and results in the presence
of a sub-population of cells with retained expression of
pluripotency factors in postnatal life [1–3]. Around puberty,
the hormonal changes and re-organisation of the testes
required to support spermatogenesis are hypothesised to
promote increased proliferation and gain of invasive
capacity of the GCNIS cells, resulting subsequently in
formation of TGCTs. The two main types of TGCTs
are seminoma (SEM) and non-seminoma (non-SEM),
where the latter may contain undifferentiated embry-
onal carcinoma (EC) as well as the more differenti-
ated yolk sac tumour (YST), choriocarcinoma (CHC)
and teratoma (TER) components [4].
Treatment of TGCTs depends on the tumour subtype
and stage, with generally excellent cure rates even for ad-
vanced disease. In most cases, orchiectomy followed by
surveillance is sufficient, but TGCTs that metastasise
(most often non-SEMs) may require a combination of sur-
gery, chemotherapy and in a few cases radiation therapy
[5]. TGCTs are generally highly sensitive to cisplatin-
based chemotherapy presumably due to their fetal germ
cell origin, but the mechanisms underlying this overall
high cisplatin-sensitivity of TGCTs and occasional treat-
ment resistance, are not understood in detail [6, 7]. An as-
sociation between the embryonic phenotype of the
majority of TGCTs and high cisplatin-sensitivity has been
established, whereas the differentiated types of TGCTs,
such as TER and CHC, are generally considered more re-
sistant to treatment [8]. The relationship between expres-
sion of pluripotency factors and cisplatin-sensitivity has
also been examined in a TGCT-derived EC cell line, in
which loss of pluripotency factor expression by siRNA-
mediated knockdown of OCT4, resulted in decreased sen-
sitivity to cisplatin [9]. Moreover, treatment with retinoic
acid to induce differentiation of the EC-derived NTera2
cell line along the neuroectodermal lineage, resulted in de-
creased expression of the pluripotency factor OCT4 and
increased cisplatin-resistance [10–12], thus supporting the
association between pluripotency factor expression and
cisplatin-sensitivity. Although cisplatin-based chemother-
apy has provided high cure rates for TGCTs, the treat-
ment regimen is associated with long-term complications,
including cardiovascular side effects and infertility as well
as relapse [5, 13]. Therefore, optimisation of the current
treatment regimen would be beneficial.
Despite the general understanding that expression of
pluripotency factors is a hallmark of GCNIS and the ma-
jority of TGCTs, the underlying molecular mechanisms
responsible for the maintenance or re-activation of pluri-
potency factor expression in these malignant germ cells
are not well understood. Several independent studies
have implicated the Nodal signalling pathway in the
pathogenesis of TGCTs [12, 14–19]. Recently, we found
that stimulation of the Nodal pathway in human fetal
testes prolonged the expression of OCT4 in gonocytes,
thus directly implicating the pathway in the regulation
of the gonocyte to pre-spermatogonia transition during
human fetal testis development [19] and involvement in
regulating pluripotency factor expression in fetal germ
cells (reviewed in [20]). Furthermore, high expression of
the Nodal signalling factors NODAL, LEFTY1 and CRIPTO
has been reported in GCNIS cells, TGCTs and TGCT-
derived cell lines [12, 16, 17], and several studies have found
co-expression of Nodal signalling and pluripotency factors
in NTera2 cells [12, 15]. Also, heterogeneous expression of
the co-receptor CRIPTO was found in NTera2 cells, with
highest expression in the subpopulation of cells displaying
the most tumorigenic potential [15].
Nodal and Activin signal through essentially the same
receptors, including the activin receptors type 1 (Alk4/7)
and type 2 (ActRIIA/IIB). An important difference is
that Nodal also requires the presence of the co-receptor
Cripto for signal transduction. Among the target genes
of the Nodal pathway are Nodal itself and the endogen-
ous inhibitor Lefty1/2, which blocks the formation of the
receptor complex by binding Nodal directly or by inter-
acting with Cripto [21]. The endogenous inhibitor of
Activin signalling is Follistatin, which binds directly to
Activin to inhibit this pathway. In recent years, Nodal
signalling has emerged as a promising therapeutic target
due to its aberrant re-expression and signalling in vari-
ous types of cancers, including breast cancer, melanoma,
prostate cancer and pancreatic cancer [22–26]. Interest-
ingly, we found that simultaneous inhibition of Nodal
and Activin signalling resulted in an almost complete
loss of gonocytes in human fetal testes [19]. Despite the
implication of the Nodal signalling pathway in the
pathogenesis of TGCTs, the mechanisms by which this
signalling pathway is dysregulated in TGCTs remain to
be elucidated. Therefore, we hypothesised that dysregu-
lation of the Nodal signalling pathway is involved in the
regulation of pluripotency factor expression and prolifera-
tion in malignant germ cells, and thus is associated with the
characteristically high cisplatin-sensitivity of these cells.
Methods
The aim of the this study was to investigate the involve-
ment of Nodal signalling in the regulation of pluripo-
tency factor expression, tumour cell proliferation and
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cisplatin-sensitivity in malignant germ cells by experi-
mental manipulation of this pathway in NTera2 cells
in vitro and in a xenograft model as well as in primary
ex vivo cultures of adult testis tissue containing GCNIS
cells.
Human tissue sample collection and preparation
Tissue samples used in this study were collected accord-
ing to the Helsinki Declaration following approval by the
regional ethics committee (H-1-2012-007) and all pa-
tients gave their informed written and oral consent prior
to surgery. Testicular tissue with and without presence
of GCNIS cells and testicular tumour samples were ob-
tained after orchiectomy for testicular cancer. Tissue
samples were transported to the Pathology Department
(Copenhagen University Hospital) immediately after the
orchiectomy where a pathologist examined the testes,
dividing it into tumour and macroscopically normal
areas. The majority of the tissue was used for diagnostic
evaluation, while the remaining tissue was allocated to
research and either snap-frozen and stored at -80 °C or
fixed in formalin or Bouin’s fixative. Alternatively, the
collected testis tissues were placed in cell culture media,
immediately transported to the laboratory and set up in
ex vivo culture as described below. Testis specimens in-
cluded samples of ‘normal testis (NT)’, samples containing
GCNIS, SEM, EC and TER (only used for gene expression
analysis). Tissue fragments with normal morphology and
containing complete spermatogenesis without the pres-
ence of malignant germ cells were used as ‘normal adult
testis’ controls. All tissue samples were evaluated by an ex-
perienced pathologist using a panel of immunohistochem-
ical markers to characterise GCNIS cells and tumour
subtypes, including placental-like alkaline phosphatase
(PLAP), podoplanin (PDPN/D2–40), OCT4 (POU5F1),
and (for non-SEMs only) also alpha-fetoprotein (AFP) and
beta-choriogonadotropin (hCG) [27]. Frozen tissue speci-
mens used for gene expression analysis were sectioned
from each end of the tissue fragment and evaluated using
immunohistochemistry to confirm the histological tumour
subtype prior to RNA extraction.
Immunohistochemistry
Immunohistochemistry on formalin-fixed tissue was per-
formed as previously described in detail [28]. The fixed tissue
samples were dehydrated, paraffin-embedded and sectioned
(4 μm). Immunohistochemistry on Bouin’s fluid-fixed testicu-
lar tissue, TGCT samples and formalin-fixed NTera2 cells
grown on glass slides was conducted using a pressure cooker
for antigen-retrieval as previously described [19]. Visualisa-
tion was performed with ImmPACT DAB peroxidase sub-
strate (Vector Laboratories, Burlingame, CA, US). Primary
antibodies, dilutions and retrieval buffers are listed in Table 1.
All sections were counterstained with Mayer’s haematoxylin
before mounting with Aquatex (Merck, Kenilworth, NJ, US).
Positive and negative controls were included for both
protocols. Positive control samples included tissue/cells
known to express the studied protein, including OCT4
(adult testes with GCNIS cells), NODAL, CRIPTO, LEFTY
(mouse fetal testes and EC tumours), cPARP (adult testes,
nuclease-treated) and BrdU (fetal testis culture, BrdU-
treated). Negative controls were processed with the primary
antibody replaced by the dilution buffer alone with none of
the negative controls exhibiting any staining. Sections were
evaluated using a Nikon Microphot-FXA microscope, subse-
quently scanned using a Nano-Zoomer 2.0 HT (Hamamatsu
Photonics, Herrsching am Ammersee, Germany) and ana-
lysed using the software NDPview version 1.2.36 (Hamama-
tsu Photonics).
Quantitative RT-PCR
Quantitative RT-PCR (RT-qPCR) was performed as pre-
viously described [19] using the QuantStudio 3 Real-
Time PCR System (Thermo Fisher, Rochester, NY, US).
In brief, mRNA was extracted from frozen tissue specimens
and cell lines using the RNAqueous Micro Kit (Ambion,
Austin, TX, US) or Nucleospin RNA purification kit
(Macherey-Nagel, Düren, Germany), respectively. cDNA
was synthesised using 1 μg mRNA, a dT20 primer and ran-
dom hexamers, resulting in 100 μl cDNA, with 1 μl cDNA
used for each RT-qPCR reaction. Gene expression was ana-
lysed using specific primers (Table 2) designed to span
intron-exon boundaries. All primers had previously been
verified (Eurofins Genomics, Ebersberg, Germany). cDNA
Table 1 Antibody dilutions, retrieval buffer and details. Antigen-retrieval buffers: citrate buffer, 10 mM, pH 6.0; TEG buffer, 10 mM Tris,
0.5 mM EGTA, pH 9.0
Antibody Dilution Retrieval buffer Species Company Cat. Number
OCT4 1:50 TEG Mouse Santa Cruz Sc-5279
NODAL 1:800 Citrate Mouse Abcam Ab55676
CRIPTO 1:200 Citrate Rabbit Abcam Ab19917
LEFTY 1:4000 Citrate Rabbit Abcam Ab22569
cPARP 1:100 Citrate Rabbit Cell Signaling 5625
BrdU 1:100 Citrate Mouse Dako M0744
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used for gene expression analysis in this study have also
been used in a previous study [29]. RT-qPCR analyses were
measured as duplicates and triplicates for frozen tissue
specimens and cell line RNA extracts, respectively, using
Brilliant II SYBR Green qPCR Master mix (Aligent tech-
nologies, Santa Clare, CA, US). The thermal cycling
programme was: 95 °C for 15min followed 40 cycles of
95 °C for 15 s and 62 °C for 1min. Changes in gene expres-
sion were examined using the 2-ΔΔCt method [30]. Expres-
sion levels were normalised to RPS20 or RPS29 and
calculated as a ratio with NT samples or vehicle controls
set to 1.
Culture of TGCT-derived NTera2 cell line
The TGCT-derived embryonal carcinoma cell line
NTera2 was a kind gift from Professor Peter Andrews
(University of Sheffield, UK) [31]. The NTera2 cells were
cultured according to standard culture conditions. In
brief, cells were cultured in DMEM supplemented with
10% fetal bovine serum, glutamine (58.5 mg/ml), penicil-
lin (100 U/ml) and streptomycin (100 mg/ml) at 37 °C in
a 5% CO2 atmosphere. Cell media and reagents were
from Gibco (Invitrogen, Carlsbad, CA, US). For gene ex-
pression analyses and co-treatment experiments, the
ALK4/5/7 inhibitor SB431542 [32] that simultaneously
inhibits Nodal and Activin signalling (40 μM, 20 μM,
10 μM, 4 μM), recombinant Nodal (50 ng/ml), recombin-
ant Activin (50 ng/ml), recombinant Lefty (100 ng/ml),
recombinant Follistatin (100 ng/ml) and cisplatin (1 and
5 μM, stock solution 1 mg/ml dissolved in 0.9% NaCl
from EberwePharma, Unterach am Attersee, Austria)
were added to the media. SB431542 was dissolved in
DMSO, while Nodal, Activin, Lefty and Follistatin were
dissolved in PBS with 0.1% BSA or 4 mM HCl, 0.1% BSA
in PBS. The recombinant proteins were purchased from
R&D systems (Minneapolis, MN, US), while SB431542
was purchased from Sigma Aldrich (St. Louis, MO, US).
Cells were plated in 25 cm2 flasks (Nunc, Thermo
Fisher), incubated overnight before treatment was initi-
ated and during the treatment period cells were split
every 48 h with complete media change. Half of the cells
were plated in new 25 cm2 flasks and the other half were
collected for analysis. NTera2 cells used for immunohis-
tochemical analysis were grown on glass slides (Nunc™
Lab-Tek™ II Chamber Slide™ System) for 48 h followed
by fixation in 4% formalin. Slides were stored at 4 °C
until further analysis.
Cell proliferation assay
Proliferation of NTera2 cells was determined after 24 h and
48 h treatment with SB431542, and after co-treatments with
SB431542 or recombinant Lefty and cisplatin. Proliferation
was evaluated using the WST-1 assay according to the man-
ufacturer’s instructions (Roche, Basel, Schweiz). 10,000
NTera2 cells were seeded into a 96-well plate with sixteen
replicates of each sample and incubated overnight. Cells
were then treated with SB431542 (5 μM, 10 μM and 20 μM)
or vehicle control (0.1% DMSO) for 24 h and 48 h. To assess
proliferation, 1:10 WST-1 dye (Roche) in serum-free
DMEM was added to the cells for 2 h before absorbance
was measured at 450 nm and 630 nm using a FLUOstar
Omega microplate reader (BMG Labtech, Ortenberg,
Germany) or an Epoch Microplate Spectrophotometer (Bio-
tek, Brøndby, Denmark). For co-treatments, 4000 cells/well
were plated into 96-well plates with eight replicates of each
sample and allowed to attach for 6 h. Treatment with
SB431542 (5 μM and 20 μM), recombinant Lefty (100 ng/
ml) or vehicle control (0.1% DMSO) was then initiated for
48 h. Subsequently, media were removed and replaced with
media containing cisplatin (1 μM and 5 μM) or 0.9% NaCl
for 48 h. Cell proliferation was assessed with the WST-1
assay as described above.
Ex vivo culture of adult human testis samples
Testis tissue samples (NT/GCNIS) obtained from orch-
iectomised testicular cancer patients (described above)
were set up ex vivo in hanging drop cultures as de-
scribed previously [33], with a few modifications. In
brief, hanging drops were set up using 40 μl drops of
culture medium ± treatment with addition of a single
testicular fragment (1 mm3) per drop and complete
media change every 48 h. Nine tissue fragments were set
up for each treatment. Medium composition was:
DMEM:F12, penicillin (100 U/ml), streptomycin (100
Table 2 Primer sequences
Gene Forward primer 5′-3′ Reverse primer 5′-3′ Amplicon size GenBank
Accession no.
OCT4 (POU5F1) TACTCCTCGGTCCCTTTCC CAAAAACCCTGGCACAAACT 166 bp NM_002701
NANOG TGATTTGTGGGCCTGAAGAAAA GAGGCATCTCAGCAGAAGACA 60 bp NM_024865.4
NODAL AGCATGGTTTTGGAGGTGAC CCTGCGAGAGGTTGGAGTAG 160 bp NM_001329906.1
CRIPTO TCCTTCTACGGACGGAACTG ATCACAGCCGGGTAGAAATG 153 bp NM_001174136.1
LEFTY1 GCCTCGACAGTGCATCGCCTC CAAGTAAACAATGACACATTGGGC 477 bp NM_020997.4
RPS20 AGACTTTGAGAATCACTACAAGA ATCTGCAATGGTGACTTCCAC 179 bp NM_001023
RPS29 CGCTCTTGTCGTGTCTGTTCA CCTTCGCGTACTGACGGAAA 91 bp NM_001032
Harpelunde Poulsen et al. BMC Cancer          (2020) 20:349 Page 4 of 14
mg/ml), insulin, transferrin, selenium (× 1) and 10% fetal
bovine serum. Media and supplements were all pur-
chased from Gibco. Cultures were incubated for 48 h
and 4 days at 34 °C in 5% CO2. 6 h before the end of the
culture period, the testis pieces were incubated with
BrdU-labelling reagent (Invitrogen). Subsequently, tissue
fragments were fixed in 4% formalin.
siRNA-mediated knockdown of CRIPTO expression
siRNA-mediated knockdown was carried out as previously
described [12]. siRNA specific for CRIPTO (TDGF1-
HSS144243, Invitrogen), a non-specific siRNA control (MIS-
SION siRNA Universal Negative Control, SICOO1, Sigma
Aldrich) and transfection agent RNAiMAX Lipofectamine
(Life Technologies, Carlsbad, CA, US) was used. In brief,
1 × 106 NTera2 cells were seeded into a 6-well plate and at
the time of transfection cells were approximately 60–70%
confluent. A concentration of 50 nM siRNA was used. 24 h
after transfection, cells were re-plated into a 96-well plate
(4000 cells/well) or cultured in T-25 cm2 flasks for RNA ex-
tractions. After 48 h, media were removed from the 96-well
plate and replaced with media containing cisplatin (1 μM or
5 μM) or 0.9% NaCl for 48 h. Cell proliferation was deter-
mined by the WST-1 assay as described above.
Establishment of NTera2 xenografts and treatments in
NMRI nude mice
The establishment and experiments conducted in this
model were set up by technicians at Pipeline Biotech A/S
(Trige, Denmark). Animal experiments were conducted in
compliance with the Danish Animal Experiments Inspect-
orate (license number 2011/561–1956) as previously de-
scribed [10, 34], with few modifications. Briefly, 30 NMRI
male mice (Foxnu1) aged 6–8 weeks (Janvier labs, Le
Genest-Saint-Isle, France) were injected once with 2 × 106
NTera2 cells into each flank. When the tumours reached
an approximate size of 150mm3, the mice were randomly
allocated into three treatment groups of ten animals; treat-
ment group 1, cisplatin (6mg/kg i.p. once during experi-
ment), treatment group 2, cisplatin + SB431542 (6mg/kg
cisplatin i.p. once during experiment and 10mg/kg
SB431542 i.p. 3 times weekly) and treatment group 3, ve-
hicle (10mg/kg DMSO i.p. 3 times weekly). Treatment
groups 1 and 3 were also used in a separate study to re-
duce the total number of animals included (Lorenzen
et al., unpublished). Body weight and tumour volume were
measured 3 times weekly throughout the experimental
period of 14 days. Tumour volume was calculated as:
tumour volume = length × width × ½ width. At the end of
the experiment mice were euthanized by inhalation of
CO2 followed by cervical dislocation. The mice were caged
in European standard cages type II with Jeluxyl HW 300/
500 bedding and the housing and changing system was
designed to assure that MPF-status was preserved during
the study. The air was exchanged approximately 12 times
per hour and temperature was kept between 20 °C and
24 °C (controlled via the ambient ventilation system).
Light cycle was 12-h dark and 12-h light. During the en-
tire experimental period mice were fed ad libitum with
Standard diet (Altromin 1234, 600 IE D3/kg diet; Altro-
min, Lage, Germany) and UV-sterilised water were admin-
istered ad libitum. All animals were inspected on a daily
basis for their general condition. Any animal showing clin-
ical signs of moderate pain or distress, any degree of suf-
fering or clinical signs that exceed the limits of the study
specific end-point would have been humanely euthanized
according to the European and Danish legislation on ani-
mals in experimental studies.
Statistical analysis
Statistical analysis was performed using the Software
GraphPad Prism 8 (San Diego, CA, US). Differences in
gene expression and cell proliferation were tested using
a two-tailed Student’s t-test, while differences in tumour
growth were tested using a one-way ANOVA with Bon-
ferroni correction. Statistically significant differences are
indicated as * P < 0.05, ** P < 0.01 and *** P < 0.001. The
number of replicates in each experimental set-up and
statistical significance are specified in figure legends.
Results
Expression of Nodal signalling factors in normal testis,
GCNIS, testicular tumours and NTera2 cells
The expression levels of NODAL, CRIPTO and LEFTY1
were initially investigated by RT-qPCR in tissue from adult
testis samples with full spermatogenesis and no presence of
malignant germ cells (hereafter termed ‘normal testis’
(NT)), samples containing pre-invasive GCNIS cells in the
majority of tubules (GCNIS), seminoma tumour (SEM),
embryonal carcinoma tumour (EC) and teratoma tumour
(TER). OCT4 (POU5F1) and NANOG were included to ver-
ify the neoplastic content in GCNIS, SEM and EC samples.
Overall, the investigated Nodal pathway genes were all
expressed in the included samples, but at very different
levels (Supplementary Fig. 1a). In GCNIS, SEM and EC, the
expression of OCT4 (GCNIS, SEM, P < 0.05; EC, P < 0.001)
and NANOG (all P < 0.05) was significantly increased com-
pared to NT, verifying the neoplastic content within these
samples. The expression of Nodal signalling factors
NODAL (P < 0.001), CRIPTO (P < 0.05) and LEFTY1 (P <
0.001) was significantly higher in EC samples compared to
NT as well as GCNIS, SEM and TER.
Protein expression of NODAL, CRIPTO and LEFTY
(antibody detects both LEFTY1 and LEFTY2) was exam-
ined by immunohistochemistry in serial sections of NT,
GCNIS, SEM and EC. OCT4 was included as a marker of
malignant germ cells, and was detected in GCNIS, SEM
and EC, but not in NT which is in accordance with the
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expected expression pattern (Supplementary Fig. 1b).
NODAL, CRIPTO and LEFTY were expressed in all inves-
tigated samples, except NT. The expression of all three
Nodal pathway proteins was more pronounced in EC com-
pared to GCNIS and SEM, with co-expression of all three
proteins in OCT4+ EC cells. Interestingly, the expression of
NODAL, CRIPTO and LEFTY was found only in a sub-
population of GCNIS cells and expression in these cells was
low. Additionally, the expression pattern of NODAL,
CRIPTO, LEFTY and OCT4 was also examined in the EC-
derived NTera2 cell line (Supplementary Fig. 1c). Notice-
ably, CRIPTO was strongly expressed in the nuclei in
addition to the expected cytoplasmic/membranous expres-
sion. NODAL was expressed in the cytoplasm, whereas
LEFTY appeared to be present between adjacent NTera2
cells, possibly reflecting secretion from the cells.
Effects of simultaneous inhibition of Nodal and Activin
signalling on proliferation and transcriptional expression
in NTera2 cells
In order to investigate the effects of inhibiting Nodal
and Activin signalling on proliferation of NTera2 cells,
treatment experiments with the ALK4/5/7 inhibitor
SB431542 [32], were conducted. Treatment with 20 μM,
10 μM and 5 μM SB431542 had no significant effect
(P > 0.05) on proliferation of NTera2 cells after 24 h or
48 h (Fig. 1a-b). In contrast, treatment with SB431542
(40 μM, 20 μM and 4 μM) for 48 h resulted in signifi-
cantly lower expression of pluripotency factors OCT4
(40 μM and 20 μM, P < 0.01, 4 μM, P < 0.05) and
NANOG (P < 0.001) as well as NODAL, CRIPTO and
LEFTY1 (all P < 0.001) in NTera2 cells (Fig. 1c). After 7
days of treatment with SB431542 (40 μM, 20 μM and
4 μM), expression of all investigated genes remained sig-
nificantly reduced (Fig. 1d).
Effects of manipulating Nodal and Activin signalling
separately on the transcriptional expression pattern in
NTera2 cells and ex vivo cultures of adult testis tissue
To separate the effects of inhibiting or stimulating Nodal
and Activin signalling pathways individually, a series of
treatment experiments were performed in the NTera2
cell line. The Nodal pathway was stimulated by treat-
ment with recombinant Nodal (50 ng/ml) and inhibited
Fig. 1 Effects of simultaneously inhibiting Nodal and Activin signalling in the NTera2 cell line. NTera2 cells were treated with 20 μM, 10 μM and
5 μM SB431542 for a) 24 h and b) 48 h followed by assessment of cell proliferation. Experiments were set up with 16 replicates per treatment and
repeated in three independent experiments (n = 3). Cell proliferation is set to 1 in the vehicle controls. Expression of pluripotency factors (OCT4,
NANOG) and Nodal pathway genes (NODAL, CRIPTO, LEFTY1) in NTera2 cells following c) 48 h and d) 7 days of treatment with SB431542 (40 μM,
20 μM and 4 μM). RPS20 was used as reference gene. Expression level is set to 1 in the vehicle controls. Experiments were conducted in triplicates
in three independent experiments (n = 3) and measured as technical triplicates. Values represent mean ± SEM. Significant difference compared to
expression in vehicle control-treated cells, * P < 0.05, ** P < 0.01 and *** P < 0.001. Note logarithmic scale
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by treatment with recombinant Lefty (100 ng/ml). Nodal
treatment for 48 h resulted in a significant upregulation of
OCT4 (P < 0.05) and NANOG (P < 0.01) as well as NODAL
(P < 0.001), CRIPTO (P < 0.01) and LEFTY1 (P < 0.001)
(Fig. 2a). The expression of OCT4 and CRIPTO (both P <
0.01) remained upregulated after 7 days of treatment with
recombinant Nodal (Fig. 2b). In contrast, Lefty treatment
for 48 h significantly reduced the expression level of all in-
vestigated genes; OCT4 (P < 0.05), NODAL (P < 0.05),
NANOG (P < 0.01), CRIPTO (P < 0.01) and LEFTY1 (P <
0.001) (Fig. 2a). The expression of OCT4 (P < 0.01),
NANOG (P < 0.001), NODAL (P < 0.01), CRIPTO (P < 0.01)
and LEFTY1 (P < 0.001) continued to be downregulated fol-
lowing Lefty treatment for 7 days (Fig. 2b). The Activin
pathway was stimulated using recombinant Activin A (50
ng/ml) and inhibited using recombinant Follistatin (100 ng/
ml). Activin treatment resulted in significantly higher ex-
pression of NANOG (P < 0.05) and LEFTY1 (48 h, P < 0.05;
7 days, P < 0.01) at both 48 h and 7 days (Fig. 2c-d), with in-
creased expression of CRIPTO (P < 0.05) also after 48 h.
Follistatin treatment increased only the expression of
NANOG (P < 0.05) after 48 h.
To examine the effects of manipulating Nodal and Acti-
vin signalling in malignant germ cells preserved within
their somatic niche, the effects of SB431542, recombinant
Nodal and Activin A were investigated in cultures of pri-
mary testis tissue from testicular cancer patients (Fig. 3
and Fig. 4). Tissue containing tubules with GCNIS cells
(located adjacent to the TGCT tumour in the orchiecto-
mised testis) from three patients was cultured ex vivo for
48 h (Fig. 3) and 4 days (Fig. 4). None of the treatments
significantly affected (P > 0.05) proliferation (BrdU+/
mm2), apoptosis (cPARP+/mm2) or number of GCNIS
cells (OCT4+/mm2) compared to the vehicle controls after
48 h (Fig. 3b-e) or 4 days (Fig. 4a-d).
Effects of pharmaceutical inhibition of Nodal and Activin
signalling on cisplatin-sensitivity in NTera2 cells
To determine whether co-treatment with inhibitors of
the Nodal signalling pathway affects cisplatin-sensitivity,
NTera2 cells were treated with SB431542 (5 μM and
20 μM) or recombinant Lefty (100 ng/ml) for 48 h
followed by 48 h of cisplatin treatment (1 μM and 5 μM).
Subsequently, effects on cell proliferation was assessed.
Fig. 2 Effects of manipulating Nodal and Activin signalling separately in NTera2 cells. Expression of pluripotency factors (OCT4, NANOG) and Nodal
signalling factors (NODAL, CRIPTO, LEFTY1) in NTera2 cells following a) 48 h and b) 7 days of treatment with recombinant Nodal (50 ng/ml) and
Lefty (100 ng/ml) and c) 48 h and d) 7 days of treatment with Activin A (50 ng/ml) and Follistatin (100 ng/ml). RPS20 was used as reference gene.
Expression level is set to 1 in the vehicle controls. Experiments were conducted in triplicates in three independent experiments (n = 3) and
measured as technical triplicates. Values represent mean ± SEM. Significant difference compared to expression in vehicle control-treated cells, *
P < 0.05, ** P < 0.01 and *** P < 0.001. Note logarithmic scale
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Co-treatments were conducted in three independent
experiments, with similar results obtained between the
experiments (Fig. 5a). Overall, initial exposure to SB431542
or Lefty followed by cisplatin treatment did not affect the
cisplatin-sensitivity in the NTera2 cells. However, co-
treatment with 20 μM SB431542 and 1 μM cisplatin signifi-
cantly increased (P < 0.05) proliferation compared to
cells treated with 1 μM cisplatin only, indicating that
Fig. 3 Effects of manipulating Nodal and Activin signalling in GCNIS cells cultured ex vivo for 48 h. a) Schematic illustration of the experimental
ex vivo hanging drop culture approach. b) Immunohistochemical staining with BrdU (proliferation marker), cPARP (apoptosis marker) and OCT4
(pluripotency marker) in adult testis tissue containing GCNIS cells treated with SB431542 (20 μM), recombinant Nodal (50 ng/ml), Activin A (50 ng/
ml) or vehicle for 48 h. Sections were counterstained with Mayer’s haematoxylin. Scale bar corresponds to 100 μm. Quantification of the number
of c) BrdU+ cells per mm2, d) cPARP+ cells per mm2 and e) OCT4+ cells per mm2. Number of positive cells is normalised to vehicle controls (set
to 1), and only apoptotic GCNIS cells were quantified. Tissue from three patients was evaluated (n = 3). Top panel of c-e) shows results from the
individual patient samples, while bottom panel represents mean ± SEM
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the cells were less sensitive to the cisplatin treatment
(Fig. 5b). Generally, there was a tendency towards re-
duced cisplatin-sensitivity when cells were co-treated
with SB431542 and cisplatin regardless of the doses
used, although for most combinations of doses this
was not statistically significant (P > 0.05).
Fig. 4 Effects of manipulating Nodal and Activin signalling in GCNIS cells cultured ex vivo for 4 days. a) Immunohistochemical staining with BrdU
(proliferation marker), cPARP (apoptosis marker) and OCT4 (pluripotency marker) in adult testis tissue containing GCNIS cells treated with
SB431542 (20 μM), recombinant Nodal (50 ng/ml) or vehicle for 4 days. Sections were counterstained with Mayer’s haematoxylin. Scale bar
corresponds to 100 μm. Quantification of the number of b) BrdU+ cells per mm2, c) cPARP+ cells per mm2 and d) OCT4+ cells per mm2. Number
of positive cells is normalised to vehicle controls (set to 1), and only apoptotic GCNIS cells were quantified. Tissue from three patients was
evaluated (n = 3). Top panel of b-d) shows results from the individual patient samples, while bottom panel represents mean ± SEM
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Effects of siRNA-mediated knockdown of CRIPTO
expression on cisplatin-sensitivity in NTera2 cells
In order to examine whether the tendency towards re-
duced cisplatin-sensitivity found after inhibition of
Nodal signalling (with SB431542) could be verified, the
effect of CRIPTO knockdown on cisplatin-sensitivity was
examined. Expression of the co-receptor CRIPTO, obli-
gate for Nodal signalling, was knocked down in NTera2
cells by a siRNA approach. Subsequently, NTera2 cells
were treated with cisplatin (1 μM and 5 μM) for 48 h and
cell proliferation was assessed. The expression of CRIPTO
was significantly reduced (P < 0.05) upon transfection with
siCRIPTO compared to the siCTRL (Fig. 6a-b) in all indi-
vidual experiments and when combined. Despite the sig-
nificant reduction in CRIPTO expression (P < 0.05), no
effect on cisplatin-sensitivity was found in the NTera2
cells when compared to the siCTRL-transfected NTera2
cells treated with cisplatin (Fig. 6c-d).
Effects of simultaneous inhibition of Nodal and Activin
signalling on cisplatin-sensitivity in a NTera2 xenograft
mouse model
Simultaneous inhibition of Nodal and Activin signalling by
SB431542 treatment in combination with cisplatin treat-
ment was subsequently investigated in an NTera2 xenograft
mouse model. NTera2 cells were injected into the flanks of
nude mice and after the development of tumours, treatment
was initiated. The animals were treated with either cisplatin
alone, a combination of cisplatin + SB431542 or vehicle con-
trol. None of the animals exhibited observable negative ef-
fects of the experimental procedure or treatments. In the
vehicle-treated control mice, tumour burden continued to
increase throughout the experimental period (Fig. 7), while
in mice treated with cisplatin alone and cisplatin +
SB431542, the tumour size was significantly reduced (P <
0.01 and P < 0.001) compared to the vehicle controls already
3 days after the treatments were initiated. However, no sig-
nificant difference (P > 0.05) in tumour size was found be-
tween mice treated with cisplatin alone and cisplatin +
SB431542 at any of the evaluated time-point (Fig. 7).
Discussion
In the present study, we found high expression of the
Nodal signalling factors in undifferentiated types of
TGCTs and our results suggest that the Nodal pathway
may be involved in the regulation of pluripotency factor
expression in malignant germ cells. However, targeting
Nodal signalling in the EC-derived NTera2 cell line by
several different experimental approaches did not affect
proliferation of the malignant germ cells or result in any
pronounced effects on cisplatin-sensitivity, indicating
that the Nodal pathway may not represent a promising
clinical target to augment the effect of current chemo-
therapy regimens in testicular cancer patients.
NODAL, CRIPTO and LEFTY1/2 were expressed at
transcript and protein levels in GCNIS cells and the undif-
ferentiated TGCTs, SEM and EC. The most pronounced
expression of all Nodal pathway factors was found in EC
and co-expressed in OCT4+ cells. In accordance with pre-
vious studies [14, 16, 18], the expression of Nodal factors
in ‘normal’ testis without malignant cells was low/absent,
suggesting maintenance of Nodal factor expression in
GCNIS and/or re-activation in malignant germ cells. Add-
itionally, the overall expression of the Nodal factors at
both gene and protein levels in GCNIS and SEM was
lower compared to EC which is in accordance with a pre-
vious study [18]. Interestingly, the protein expression of
the Nodal pathway factors was less pronounced in GCNIS
cells compared to EC but also to some extent SEM, which
supports the notion that Nodal signalling components
Fig. 5 Effects of pharmaceutical inhibition of Nodal/Activin or Nodal signalling on cisplatin-sensitivity in NTera2 cells. NTera2 cells were treated for
48 h with SB431542 (5 μM and 20 μM) or Lefty (100 ng/ml) followed by additional 48 h of cisplatin treatment (1 μM and 5 μM) and assessment of
cell proliferation. a) Experiments were conducted in three independent experiments with eight replicates per treatment (shown as mean for each
experiment). Cell proliferation is set to 1 in NTera2 cells not treated with cisplatin. b) Values represent mean ± SEM from the three independent
experiments (n = 3). Significant difference compared to proliferation of vehicle-treated control NTera2 cells receiving corresponding cisplatin
treatment, * P < 0.05
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might be maintained only at low levels in GCNIS cells and
are upregulated in the invasive tumours, although it re-
mains to be determined whether the Nodal pathway is in-
volved in the transition from GCNIS to EC/(SEM). The
observed high expression of LEFTY1/2 in undifferentiated
TGCTs, indicates that the inhibitory feedback mechanism
on Nodal signalling may not be dysregulated in TGCTs,
despite a previous study suggested this based on the re-
ported low expression of LEFTY1 in EC [16].
The Nodal signalling factors were all expressed in the
NTera2 cell line, hence we used it as a model to examine
effects of manipulating Nodal signalling in TGCTs. Sim-
ultaneous inhibition of Nodal and Activin pathways did
not affect proliferation in NTera2 cells or in GCNIS cells
in ex vivo cultured testis samples. Since Nodal and Acti-
vin signalling have been implicated in germ cell survival
in both human and mouse fetal testes [19, 35], this may
indicate a difference between normal fetal gonocytes and
malignant germ cells, although it is important to con-
sider that in contrast to normal fetal germ cells, malig-
nant TGCTs have acquired features allowing them to
survive outside of their normal niche. In the NTera2
cells, simultaneous inhibition of Nodal and Activin sig-
nalling resulted in reduced expression of the investigated
pluripotency factors and Nodal pathway genes, and after
separating the effects of Nodal and Activin signalling
Fig. 6 Effects of siRNA-mediated knockdown of CRIPTO expression on cisplatin-sensitivity in NTera2 cells. Expression of CRIPTO determined by RT-
qPCR after knockdown using a siRNA targeting CRIPTO (siCRIPTO) and a non-specific siRNA control (siCTRL). RPS29 was used as reference gene. a)
Experiments were conducted in four independent experiments (n = 4) and measured as technical triplicates (shown as mean for each
experiment). Expression level of CRIPTO is set to 1 in vehicle-treated control NTera2 cells. b) Values represent mean ± SEM from the four
independent experiments. Significant difference compared to expression level of CRIPTO in siCTRL-transfected NTera2 cells, * P < 0.05. Following
knockdown, cells were subjected to treatment with 1 μM and 5 μM cisplatin for 48 h and cell proliferation was assessed. c) Experiments were
conducted in four independent experiments and set up with eight technical replicates per treatment. d) Values represent mean ± SEM from the
four independent experiments. Cell proliferation is set to 1 in vehicle-treated control NTera2 cells not treated with cisplatin
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pathways it was evident that the Nodal pathway was re-
sponsible for the majority of observed effects. Addition-
ally, the opposing effects observed after stimulating and
inhibiting Nodal signalling, suggest that the pathway
may be involved in the regulation of pluripotency factor
expression in malignant germ cells. These results are in
accordance with the reported involvement of Nodal sig-
nalling in regulating pluripotency factor expression in
human fetal testes [19], mouse fetal testes [16, 36, 37]
and human embryonic stem cells [38]. However, ma-
nipulation of Nodal and Activin signalling in ex vivo cul-
tures of GCNIS-containing tissue (48 h and 4 days) did
not overall affect the number of OCT4+ GCNIS cells, al-
though in one patient sample an increased number of
OCT4+ GCNIS cells was observed following treatment
with Nodal and Activin (48 h) and Nodal (4 days). The
different responses between patient samples as well as
the relative short-term culture periods used in this study,
suggest that additional studies examining the effects of
stimulated Nodal/Activin signalling on GCNIS cells may
be relevant. Importantly, the overall low number of apop-
totic germ cells and the presence of proliferating cells in
the cultured tissue samples, suggest that the tissue was
supported by the culture approach and that the selected
treatment doses were not toxic. However, given the high
variation in the tissue, which is expected in testicular can-
cer patients [33], minor effects of treatments can be diffi-
cult to detect using this experimental approach.
Aberrant re-activation of Nodal signalling has been re-
ported in various types of cancers, including cancer stem
cells which also express pluripotency factors, and several
studies have shown that inhibition of Nodal/(Activin) sig-
nalling reduces the tumorigenic potential both in vitro and
in cancer mouse models [22–26]. Additionally, combined
treatment with the SB431542 inhibitor and chemotherapy
(gemcitabine) abolished tumours in a pancreatic cancer
mouse model and resulted in complete survival of mice in
this treatment group [24]. Moreover, given the almost
complete germ cell loss following SB431542 treatment of
human fetal testes, we examined whether co-treatment
with this inhibitor could augment cisplatin-sensitivity in
NTera2 cells. Overall, we did not observe pronounced
effects on cisplatin-sensitivity following inhibition of Nodal
signalling in vitro or in the xenograft model, except tenden-
cies toward reduced cisplatin-sensitivity after in vitro
pharmaceutical inhibition of Nodal/Activin signalling and
siRNA-mediated knockdown of the obligate co-receptor
CRIPTO. In vitro treatment with recombinant Lefty to in-
hibit only Nodal signalling did not result in reduced
cisplatin-sensitivity (or showed tendencies in this direction),
which could reflect the different levels at which inhibitory
molecules and siRNA-mediated knockdown functions [39].
Additionally, the slightly increased cisplatin-resistance ob-
served following blockage of both Nodal and Activin signal-
ling (using the high dose of SB431542), but not after
specific inhibition of Nodal signalling, could indicate some
redundancy between the Nodal and Activin pathways.
We speculate that inhibition of Nodal signalling pro-
motes downregulation of pluripotency factor expression
in the malignant germ cells driving them towards a
more differentiated phenotype, which is associated with
reduced cisplatin-sensitivity [8–12]. However, since
both ECs (high Nodal expression) and SEMs (low Nodal
expression) are highly sensitive to cisplatin-based treatment
[6, 7], this may explain why we did not find pronounced
effects on cisplatin-sensitivity upon manipulation of the
Nodal signalling pathway. It has previously been demon-
strated that calcitriol treatment (active form of vitamin D)
Fig. 7 Effects of inhibiting Nodal/Activin signalling on cisplatin-sensitivity in a NTera2 xenograft model. NTera2 cells (2 × 106; single injection) were
xenografted into the flanks of nude mice and allowed to grow to an average size of 150mm3. Animals were allocated into three groups (n = 10 for
each group) and treated (day 0 on graph) with vehicle (10mg/kg DMSO i.p. three times weekly), cisplatin (6mg/kg i.p. once during the experiment) or
cisplatin + SB431542 (6mg/kg cisplatin i.p. once during the experiment and 10mg/kg SB431542 i.p. three times weekly). Body weight and tumour size
(mm3) were evaluated three times weekly during the experimental period of 11 days. Values represent mean ± SEM. Significant difference compared to
vehicle control-treated mice, * P < 0.05, ** P < 0.01 and *** P < 0.001. Abbreviations: i.p., intraperitoneal injection
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of NTera2 cells resulted in both decreased expression of
pluripotency factors and augmented effects of cisplatin,
while treatment of NTera2 with retinoic acid decreased
the expression of pluripotency factors and reduced
cisplatin-mediated effects [10, 34]. This suggests that
the relationship between pluripotency factor expression
and cisplatin-sensitivity in malignant germ cells is not
completely understood and that further studies examin-
ing this would be relevant.
Conclusions
In conclusion, the Nodal signalling factors are highly
expressed in the undifferentiated types of TGCTs and may
be involved in the regulation of pluripotency factor expres-
sion in malignant germ cells. In contrast to several other
types of cancers in which the Nodal pathway is also re-
activated, inhibition of Nodal (and Activin) signalling did
not affect tumour cell proliferation or augment cisplatin-
sensitivity in TGCTs in vitro or in the xenograft model.
Thus, the different response to the pharmaceutical pathway
inhibitor SB431542 in TGCTs compared to human fetal
germ cells, suggests that regulation or feedback mechanisms
related to the Nodal pathway may be altered in malignant
germ cells, although additional studies are needed to exam-
ine these mechanisms in more detail.
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Additional file 1: Figure S1. Expression of Nodal signalling factors in
testis, GCNIS cells, TGCTs and TGCT-derived NTera2 cells. a) Expression
level of OCT4, NANOG, NODAL, CRIPTO and LEFTY1 in testis tissue with
complete spermatogenesis and no malignant germ cells (NT), testis sam-
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used as reference gene. Expression level is set to 1 in NT samples. Tissue
samples from eight patients were included (n = 8) and measured as tech-
nical duplicates. Values represent mean ± SEM. Significant difference com-
pared to expression in NT samples, * P < 0.05, ** P < 0.01 and *** P <
0.001. Note logarithmic scale. b-c) Expression of Nodal signalling factors
NODAL, CRIPTO and LEFTY (antibody detects both LEFTY1 and LEFTY2)
determined by immunochemical analysis in serial sections of NT, GCNIS,
SEM and EC and TGCT-derived NTera2 cells. OCT4 is included as a marker
of malignant germ cells. Sections were counterstained with Mayer’s
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